Taiwan Liposome Company Completes Trial Enrollment For Arthritis Treatment

Taiwan Liposome Company, which applies proprietary drug delivery technologies to approved drugs, reported the Phase I/II clinical trial of its arthritis drug is now fully enrolled. TLC599 is a corticosteroid encapsulated in a lipid using TLC's BioSeizer platform. Because of its innovative formulation, TLC is administered by a small needle, allowing use in small joints such as the hand. Also, its sustained release provides longer relief from arthritis stiffness and pain. TLC expects to report results from the trial later in 2016, following the 12-week observation period.